Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02077998 · ClinicalTrials.gov registry record · Early Phase 1
Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Early Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT02077998 is a Early Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 1 participants.
The verdict
NCT02077998, a Early Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase 0/II trial studies the effect of carbon C 14 oxaliplatin in tumor tissue and blood and the side effects and how well oxaliplatin works in treating patients with metastatic breast cancer. DNA analysis of tumor tissue and blood samples from patients receiving carbon C 14 oxaliplatin may help doctors predict how well patients will respond to treatment with oxaliplatin. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interventions
- OTHER laboratory biomarker analysis
- DRUG oxaliplatin
- RADIATION carbon C 14 oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02077998
The ClinicalTrials.gov registry entry for NCT02077998 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT02077998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02077998 about?
NCT02077998 is a clinical study titled "Oxaliplatin in Treating Patients With Metastatic Breast Cancer". This phase 0/II trial studies the effect of carbon C 14 oxaliplatin in tumor tissue and blood and the side effects and how well oxaliplatin works in treating patients with metastatic breast cancer. DNA analysis of tumor tissue and blood samples from patients receiving carbon C 14 oxaliplatin may hel...
What is the current status of trial NCT02077998?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2015-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02077998?
The interventions under investigation include: laboratory biomarker analysis (OTHER), oxaliplatin (DRUG), carbon C 14 oxaliplatin (RADIATION).
Who is sponsoring clinical trial NCT02077998?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.